Novartis posts second-quarter profit beat, keeps 2021 guidance

  • It generated net profit of $3.72 billion and increased core operating income 18% to $4.35 billion.
  • While sales in the three months through June rose 14% to $12.96 billion, a gain of 9% when stripping out currency fluctuations.

Novartis boosted its second-quarter core net income by a fifth, beating market expectations, the Swiss drugmaker reported on Wednesday, as it kept its 2021 guidance.

It generated net profit of $3.72 billion and increased core operating income 18% to $4.35 billion while sales in the three months through June rose 14% to $12.96 billion, a gain of 9% when stripping out currency fluctuations.

Analysts polled by Refinitiv had on average expected net profit of $3.46 billion on revenue of $12.52 billion.

Novartis said its key drug brands were performing well and its product development pipeline continued to progress.

"While demand is starting to return to pre-COVID-19 levels in most geographies and therapeutic areas, we still see a slight impact on parts of our business for example in oncology, generics and certain geographies," it said.

"We are assuming further easing of COVID-19 restrictions in the second half of the year with a positive impact on business dynamics."

It reiterated it expected 2021 sales to grow at a low- to mid-single-digit percentage rate, with core operating income seen growing at a mid-single-digit percentage rate ahead of sales.

CNBC Health & Science

Read CNBC's latest global coverage of the Covid pandemic:

'If anybody is lying here senator, it is you,' Fauci tells Sen. Paul in heated exchange at Senate hearing 

Delta variant now accounts for 83% of all sequenced Covid cases in the U.S.

Singapore tightens restrictions again as Covid cases rise

WHO chief warns that the world is going into the 'early stages of another wave'

Source: Read Full Article